Lattice Biologics Inc. is going public!
We have some great news inside this issue...
This is our biggest announcement to date. In what will be the culmination of our past year and a half of scientific research and analysis, professional partnerships, and raising capital, Lattice Biologics is thrilled to announce a proposed merger with Vancouver-based Blackstone Ventures Inc. (Blackstone).
This agreement will provide the support and resources to take Lattice to the next level and fulfill our dream of bringing this very determined company to the public market.
As we enter into this next phase, we are honored to be joined by three new Board Members who bring incredible expertise and proven track records for raising capital.
Click through for the official press release and to meet our new Board Members.
As always, be sure to share your news and stories with us, too!
Lattice Biologics, Inc.
Lattice Announces Proposed Merger with Blackstone Ventures
August 13, 2015 - Lattice Biologics Inc. ("Lattice") is pleased to announce that it has entered into a letter of intent (LOI) with Blackstone Ventures Inc. (TSX-V: BLV), a company listed on the TSX Venture Exchange. Pursuant to the LOI, Blackstone is proposing to acquire all of the issued and outstanding securities of Lattice. The Transaction will constitute a reverse takeover of Blackstone by Lattice with the resulting combined company being publicly listed on the TSX Venture Exchange.
Lattice Biologics is partnered in developing new regenerative medicine technologies to address widespread unmet clinical needs. These stem cell based technologies will advance the field of personalized medicine for spinal fusion, breast reconstruction, cartilage repair, and cancer diagnostics. Assembling a world renowned team of key opinion leaders, the Company is well poised to commercialize its patent pending technology for multiple indications.
The Company's board of directors will include one nominee appointed by Blackstone. Lattice's principal shareholders, Guy Cook, Chief Executive Officer and Cheryl Farmer, Chief Financial Officer will serve as CEO and CFO of the Company following completion of the business combination and Gregory Davis will serve as COO.
"This team offers true depth across an indispensable range of expertise, which allows us to draw on beneficial contacts in M&A, Canadian government resources, and U.S. regulatory authorities. Through the collaboration and focus of such a dedicated group of professionals, we are highly confident that we will execute our stem cell-based technologies to advance personalized medicine.
"We recognize this is an excellent time to bring our products and services to market and we have assembled the best senior managers to accomplish our growth goals. I am incredibly fortunate to partner with each one of these talented individuals."
- Guy Cook
(Fun fact about Guy: "If it doesn't blow smoke or make noise, it is not a sport.")
New Board Member
Mr. McInnes comes to Lattice as a natural resources entrepreneur who began funding ideas through Canadian capital markets in 1993.
Donald is the founder and former CEO of Plutonic Power Corporation, a British Columbia-based renewable power development company with a broad portfolio of clean energy projects. In 2011, Plutonic merged with Magma Energy Corp. to create Alterra Power Corp., a diversified clean energy company with annual gross revenue in excess of $100mm. He currently serves as Alterra's Vice Chairman of the Board and Chair of the Health & Safety Committee.
Donald is a frequent public speaker, passionate contributor to the debate on public policy, and involved member of the business community. He shares his talents with a variety of boards and associations, including serving as Past Chair of the Board of Prostate Cancer Canada, Chairman of the Clean Energy Association of British Columbia, and Governor of the British Columbia Business Council, among many others. In the past four years, he has been awarded an Ernst and Young Entrepreneur of the Year Award in the Pacific Division Cleantech category, the Queen's Diamond Jubilee Medal, and the Clean Energy Association of British Columbia's Lifetime Achievement Award.
"My seven years of association at Prostate Cancer Canada have given me a window into the evolution of leading edge medical care. I am attracted to Lattice due to Guy Cook's experience and successful history of in the medical field. Knowing Guy is fully committed with his time and capital, I am very attracted to Lattice as an investor. Lattice is a niche player that is carving out a unique base business in allograft with tremendous upside in the emerging field of stem cell research.
"I think this company will have the right people involved to become an unparalleled success and I look forward to helping in any way I can."
Fun fact:"I fractured my arm in May trying to keep up with my 10 year old mountain biking down Whistler. My poor wife. I have three kids, she has four!
New Board Member
Mr. Stifano, CPA, is currently President and CEO of Cordoba Minerals Corp. (TSX Venture: CDB), a Toronto-based junior resource exploration company focused on the exploration and acquisition of copper and gold projects in Colombia.
He joins the team as a key Board Member. Mario is a seasoned executive who brings strong capital markets experience to the Company and will be invaluable to the development and implementation of a successful mergers and acquisitions (M&A) strategy. Throughout his career, he has raised approximately $700mm in equity and debt for technology and resource companies, including raising funds for start-ups and an IPO. Mario's extensive M&A experience, including a $400 million acquisition while CFO of Lake Shore Gold, will greatly assist Lattice as the Company pursues its growth strategies.
"I am really excited and proud to be joining the Lattice Biologics Board to assist this strong and proven management team in executing its vision to aggressively grow the Company through M&A and the commercialization of its leading edge technologies."
Fun fact: Mario has a true passion for real estate and loves doing renovations.
New Board Member
Ms. Thomas, CPA, is the Founder of Paraclae, LLC, a thriving finance and accounting consulting firm that recently merged with Sensiba San Filippo, one of the largest Northern California based CPA and business consulting firms.
Cathy offers over 30 years of experience in business accounting services, including 15 years with Deloitte and Touche, five of which as a partner. Her major career accomplishments address the critical areas of complex public offerings, global corporate auditing, and Sarbanes Oxley Compliance. Most significantly, the latter of which encompasses compliance program development and implementation to protect shareholders and the general public from accounting errors and fraudulent enterprise practices and to improve the accuracy of corporate disclosures.
In 2002, she started the consulting arm of Armanino Mc Kenna, LLP, as a member of the firm's executive committee. Providing outsourced internal audit services specifically to address Sarbanes Oxley Compliance, outsourced finance, and accounting resources, the firm tripled in size across six years driven by the increase in revenue from the consulting practice. In 2008, Cathy started Paraclae from ground zero and was profitable year one.
"I am looking forward to being a part of the expected growth within Lattice and assisting from a finance perspective and providing oversight."
Fun fact: Cathy is very athletic and really enjoys playing golf.
Welcome, Dr. Richard D. Guyer, M.D., New Scientific Advisory Board (SAB) Member!
Lattice Biologics is thrilled to announce the addition of Dr. Richard Guyer, one of the first surgeons to perform spinal disc replacement in the U.S., to our SAB.
Guyer's focus on is helping patients who are appropriate disc candidates get their life back. He has performed over 500 neck and lower back disc replacements throughout the U.S. and around the world.
Dr. Guyer is the Co-founder and President of the Texas Back Institute and Director of their Spine Fellowship Program. He is also Co-director for the Center for Disc Replacement at Texas Back Institute. His other professional distinctions include:
- Fellowship, Spinal surgery, Leon Wiltse and Henry Bohlman at Case Western
- Associate Clinical Professor of Orthopedics at University of Texas Southwestern School of Medicine
- Chairman of the Board, Texas Back Research Foundation
- Past President, North American Spine Society, 2007
Some of his recent honors include the "Best Doctor Award" from D Magazine and the "Volvo Award for Low Back Pain Research."
"My medical philosophy is to treat my patients with compassion and help them make treatment decisions as if they are a family member of mine." - Dr. Richard Guyer
Based in the Dallas/Fort Worth Area, Dr. Guyer is currently an Associate Clinical Professor for the Department of Orthopedics at UT Southwestern Medical School in Dallas and on the editorial board for numerous medical journals including, Spine, The Spine Journal, The International Journal of Spine Surgery, and The European Spine Journal.
Welcome, Dr. Guyer!
| SHARE THE WORD
Know someone who might be interested in our regenerative and personalized medicine updates?
Click to share this newsletter with your team, colleagues, and contacts.
If you have received this newsletter from a friend, click the box above to sign-up and receive your own updates.
SCOTTSDALE'S "CURE CORRIDOR"
- LOCALIZED INOVATION AND COMMERCE
"Where education, research, clinical trials, and patient care delivery come together."
See what it's all about.
Watch the Video here
Lattice Biologics is located within the Cure Corridor, a concept designed to promote the innovative activities occurring around the concentration of the Bio-Life Sciences sector from Shea Boulevard to the Scottsdale Airpark.
"The Bio-Life Sciences Sector is a major driver of the innovation economy in the State of Arizona, Greater Phoenix region and City of Scottsdale. According to the Flinn Foundation, the biosciences in Arizona develop treatments for health afflictions, design diagnostics to gauge and prevent illness, strengthen our food supply, develop alternative fuel sources, and much more."
Download the Cure Corridor Brochure and Map here
|GET TO KNOW LATTICE
Lattice Biologics Inc. is an emerging leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration.
We develop, manufacture, and market biologic products to domestic and international markets.
Our products are used in a variety of applications, including:
Enhancing fusion in spine surgery
Enhancing breast reconstruction post mastectomy for breast cancer patients
Sports medicine indications, including ACL repair
Promotion of bone regeneration in foot and ankle surgery
Enhancing wound repair in burn victims
Subchondral bone defect repair in knee and other joint surgeries
Contact us today to learn more about our products and technologies.
Click here to download our Executive Summary.